Beckman Coulter Shares Drop on Troponin Test Issues
March 23, 2010
Beckman Coulter Shares Drop on Troponin Test Issues
Beckman Coulter's shares dropped around 7 percent after the firm disclosed that an ongoing issue surrounding its troponin test kits could lead to further restrictions on the test and may have a material impact on its results.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Beckman Coulter Plans FDA Submissions in May or June for Troponin Test
January 18, 2011 / GenomeWeb Daily News - Mizuho Securities Initiates Coverage on MDx Firms
October 21, 2010 / GenomeWeb Daily News - Beckman Coulter Upgraded by JP Morgan
January 4, 2010 / GenomeWeb Daily News - UK Startup DNA Electronics Developing Handheld Device to Detect Genetic Risk for Drug AEs
February 25, 2009 / Pharmacogenomics Reporter - 23andMe, MondoBiotech Collaborate to Study Genetic Risk for Rare Diseases
February 4, 2009 / Pharmacogenomics Reporter